Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of uncomplicated PID based on the absence of pelvic or tubo-ovarian abscess at pelvic ultrasound and/or laparoscopic examination.~Exclusion Criteria:~* Subjects with impaired liver and renal function; known hypersensitivity to study drugs, related compounds or any of the excipients.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Moxifloxacin (Type: EXPERIMENTAL): Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
- Levofloxacin plus Metronidazole (Type: ACTIVE_COMPARATOR): Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).